The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Efficacy of Growth Height and Peak-Luteinizing Hormone Level Suppression on Idiopathic Gonadotropin-Dependent Precocious Puberty Patient Using Herbal Remedy, Aesopjiyoun-tang

  • Received : 2015.11.11
  • Accepted : 2015.12.30
  • Published : 2015.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this report is to evaluate effect of Korean medical treatment on idiopathic gonadotropin-dependent precocious puberty (G-DPP) patient received herbal medicine. We administered Aesopjiyoun-tang remedy to idiopathic G-DPP and analyzed the delay effect by hormonal value and radiographs; the height growth effect by measurement of height. After Korean medical treatment, suppression effect to peak-Luteinizing Hormone level (LHL) is 14.39IU/L to 10.9IU/L for 13month, growth effect to height value is 11cm/13month; and change of mean growth velocity (MGV) is 6.08cm/year to 10.06cm/year. The gain in height by treatment is 3.98cm/year. The result suggests Aesopjiyoun-tang can be an effective treatment for G-DPP. Herbal medicine can be used as an alternative treatment in place of the GnRH treatment.

Keywords

References

  1. Carel JC, Leger J. Precocious puberty. The New England journal of medicine. 2008;358:2366 77. https://doi.org/10.1056/NEJMcp0800459
  2. Martin R. Early puberty: what is normal and when is treatment indicated. Horm. Res. 2003;60 (suppl3):31-4. https://doi.org/10.1159/000074497
  3. Brown JJ, Warne GL. Growth in precocious puberty. Indian journal of pediatrics. 2006;73:81-88. https://doi.org/10.1007/BF02758267
  4. Gluckman PD, Hanson MA. Evolution, development and timing of puberty. Trends in endocrinology and metabolism. 2006;17(1):7-12. https://doi.org/10.1016/j.tem.2005.11.006
  5. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab. 2002;87:2090-4. https://doi.org/10.1210/jcem.87.5.8481
  6. Kim TH, Coe HJ, Kim S, Lee SW, Chae HW, Kim YS, et.,al. Cinical and Endocrinologic Characteristics of Children Referred for Precocious Puberty. Korean J of pediatrics. 2007;12(2):119-26.
  7. Styne D, Grumbach M. Puberty: ontogeny, neuroendocri-nology, physiology, and disorders. In: Kronenberg HM, Mel-med S, Polonsky KS, Larsen PR, editors. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders Co. 2008:969-1166.
  8. Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol. 2006;254-255:217-20. https://doi.org/10.1016/j.mce.2006.04.012
  9. Lim YK, Hur KW, Park SY, Suh KS, Chun SY, Lee SJ, et al. A Case Report of Precocious Puberty in a Female Patient : Significant Improvement in Controlling the Sex Hormone Levels. J Pediatr Korean Med. 2014;28(4):64-70. https://doi.org/10.7778/jpkm.2014.28.4.064
  10. Kim JE, Yang SJ, Cho SH, Park HM. A report on the effect of jowisengchung-tang in 2 cases of precocious puberty. J Korean obstet gynecol. 2013;26(2):178-187. https://doi.org/10.15204/jkobgy.2013.26.2.178
  11. Tanner JM, Healy MJR, Goldstein H. Assessment of skeletal maturity and prediction of adult height. Oxford: Elsevier United Kingdom. 2001.
  12. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment. J Clin Endocrinol Metab. 1999;84(6):1973-8. https://doi.org/10.1210/jcem.84.6.5647
  13. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarre-van de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab. 2000;13 Suppl 1:765-72. https://doi.org/10.1515/JPEM.2000.13.S1.765
  14. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab. 2002;87(5): 2090-4. https://doi.org/10.1210/jcem.87.5.8481
  15. Partsch CJ, Hummelink R, Peter M, Sippell WG, Oostdijk W, Odink RJ, et al. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty influence on growth and predicted adult height. Horm Res. 1993;39:111-7. https://doi.org/10.1159/000182709
  16. Carel JC, Lahlou N, Guazzarotti L, Joubert -Collin M, Roger M, Colle M, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol. 1995;132:669-704.
  17. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the use of gonadotropin releasing hormone analogs in children. Pediatrics. 2009;123:e752-62. https://doi.org/10.1542/peds.2008-1783
  18. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008;159:S3-8. https://doi.org/10.1530/EJE-08-0814
  19. Zhao J, Yu J. Study on clinical application of kangzao-II recipe in treating girl gonadotropin-releasing hormone dependent sexual precocity. Chinese Journal of Integrated Traditional and Western Medicine. 2003;3:182-84.

Cited by

  1. 한약 치료를 이용한 여성 특발성 성조숙증의 임상연구에 대한 문헌고찰 vol.30, pp.3, 2015, https://doi.org/10.15204/jkobgy.2017.30.3.020
  2. CARE 지침에 따른 대한한의학회지의 증례 보고에 대한 질 평가 연구: 2015년~2020년 증례 보고를 중심으로 vol.41, pp.2, 2015, https://doi.org/10.13048/jkm.20016